Anaphylaxis
Risk of severe allergic reaction. Seek urgent medical help if serious symptoms occur.
Medicine information TRUXIMA 500mg concentrate for solution for infusion
- Product code:
- W63707001
- Quantity:
- 1
- Indicated for:
- hematologic malignancies
- Route of administration:
- infusion
- Substance:
- rituximab (monoclonal antibody)
- ATC
- L01FA01 — Antineoplastic and immunomodulating agents | Monoclonal antibodies and antibody drug conjugates | Cd20 (clusters of differentiation 20) inhibitors
Rituximab is a monoclonal antibody used in the treatment of various autoimmune diseases and hematological cancers, such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. It works by targeting the CD20 protein expressed on the surface of B lymphocytes, leading to their destruction through immune mechanisms.
Rituximab is administered intravenously, usually in cycles, and is used either as monotherapy or in combination with other chemotherapeutic or immunosuppressive agents. It is indicated to reduce disease activity, prolong remission, and improve patients' quality of life.
Common side effects include infusion reactions, fever, chills, nausea, and fatigue. In rare cases, severe adverse reactions such as serious infections, reactivation of hepatitis B, or progressive multifocal leukoencephalopathy (PML) may occur. Careful monitoring of patients during and after administration is essential.
Rituximab is a valuable therapeutic option for patients with autoimmune diseases and hematological cancers, offering significant benefits in disease control and survival extension.
Rituximab is administered intravenously, usually in cycles, and is used either as monotherapy or in combination with other chemotherapeutic or immunosuppressive agents. It is indicated to reduce disease activity, prolong remission, and improve patients' quality of life.
Common side effects include infusion reactions, fever, chills, nausea, and fatigue. In rare cases, severe adverse reactions such as serious infections, reactivation of hepatitis B, or progressive multifocal leukoencephalopathy (PML) may occur. Careful monitoring of patients during and after administration is essential.
Rituximab is a valuable therapeutic option for patients with autoimmune diseases and hematological cancers, offering significant benefits in disease control and survival extension.
General data about TRUXIMA 500mg
- Substance:
- rituximab
- Date of latest medicines list:
- 01-10-2026
- Product code:
- W63707001
- Strength:
- 500mg
- Pharmaceutical form:
- concentrate for solution for infusion
- Quantity:
- 1
- Product type:
- Generic medicine
- Price:
- 4039.00 RON
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for rituximab
Strengths available for rituximab
- 100mg
- 10mg/ml
- 120mg/ml
- 500mg
Official documents
- Added to database:
- 08/03/2017
- Source record updated:
- 29/09/2025
Warnings:
Immunosuppression / infection risk
This medicine may increase the risk of infections.
Additional monitoring
This medicine is subject to additional monitoring.
Breastfeeding warning
Use during breastfeeding only on medical advice.
Pregnancy warning
Use during pregnancy only on medical advice.
Reimbursement lists for TRUXIMA 500mg Celltrion
G17 (C1) - Major collagenosis (systemic lupus erythematosus, scleroderma)
- Price
- 4039.00 RON
- Copayment
- 3282.96 RON
- Patient payment
- 756.04 RON
GX (C1) - GENERIC (used in compensation list, C1, for another diagnosis)
- Price
- 4039.00 RON
- Copayment
- 3282.96 RON
- Patient payment
- 756.04 RON
NHP 9.1 (C2) - Spinal cord transplant
- Price
- 4039.00 RON
- Copayment
- 3282.96 RON
- Patient payment
- 756.04 RON